Back
RGT
Argent Biopharma Limited
🇦🇺 ASX
📦 LOGISTICS
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 67.50%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
7
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Argent BioPharma Ltd. engages in the production of medical marijuana. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2006-12-21. The firm is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
📈 Performance
Price History
+452.63%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.10
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in RGT
7
📊 Total Capital Earnings
$-57.02
🔃 Average investment frequency
2 days
💵 Average investment amount
$1,284
⏰ Last time a customer invested in RGT
7 days
RGT investor breakdown
💵 Income of investors
More than 200k
150k - 200k
14%
100k - 150k
29%
50k - 100k
29%
Less than 50k
29%
👶 Age of investors
18 - 25
26 - 34
14%
35 - 90
86%
🙋 Legal gender of investors
Female
43%
Male
57%
Pearlers who invest in RGT also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.08%
📊 Share price
$110.41 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
22.04%
📊 Share price
$65.86 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.08%
📊 Share price
$147.54 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
7.33%
📊 Share price
$72.68 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 8332.1m in AUM and 198 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
9.85%
📊 Share price
$148.52 AUD
🇦🇺 AUSTRALIA
💸 FINANCIALS
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
Want more shares? Try these...
RGS
Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.
🙌 Performance (5Yr p.a)
-17.54%
📊 Share price
$0.01 AUD
🧬 BIOTECHNOLOGY